Clinical Trial Update: A Study Evaluating Whether Pembrolizumab Alone or in Combination With CMP-001 Improves Efficacy of Treatment in Patients With Operable Melanoma [Phase 2]

View source ↗

Summary

A Phase 2 clinical trial update evaluating pembrolizumab alone or in combination with CMP-001 for operable melanoma, including melanoma of unknown primary, with…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Cutaneous Melanoma
• Melanoma of Unknown Primary

Drugs mentioned

• CMP-001
• KEYTRUDA (PEMBROLIZUMAB)

Snippet

Sponsor: National Cancer Institute (NCI) | Conditions: Clinical Stage III Cutaneous Melanoma AJCC v8, Melanoma of Unknown Primary | Phase 2 | Status: ACTIVE_NOT_RECRUITING